NCT00086775View on ClinicalTrials.gov

Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

July 31, 2003

Primary Completion Date

June 30, 2005

Study Completion Date

October 31, 2009

Conditions
Leukemia
Interventions
BIOLOGICAL

alemtuzumab

BIOLOGICAL

rituximab

DRUG

fludarabine phosphate

Trial Locations (5)

15224

Western Pennsylvania Cancer Institute, Pittsburgh

15232

Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh

39202

Jackson Oncology Associates, PLLC, Jackson

02115

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston

08903

Cancer Institute of New Jersey at Robert Wood Johnson University Hospital, New Brunswick

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT00086775 - Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter